# Towards Curative Therapies for Hypogonadotropic Diseases

> **NIH NIH R37** · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $825,474

## Abstract

PROJECT ABSTRACT
Kisspeptin, neurokinin B, and dynorphin signaling provide essential guidance and stimulation to GnRH neurons.
Though the past decade has seen extraordinary advances in our understanding of this signaling network, this
grant employs novel assays and receptor agonist and antagonist administration in vivo to challenge several
dogmas in reproductive endocrinology. These complementary approaches, performed in rhesus monkeys,
healthy volunteers, and patients with reproductive disease, unite two investigators with experience in genetics,
physiology, and pharmacology. This interdisciplinary collaboration is well positioned to attack the complexities
of the hypothalamic architecture that regulates GnRH secretion. Thus, by translating fluidly between monkey
and man, between juvenile and adult, and between physiology and pathophysiology, this grant aims to generate
novel insights into sexual maturation and develop new treatments for patients with reproductive disorders.

## Key facts

- **NIH application ID:** 10072296
- **Project number:** 2R37HD043341-18A1
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Stephanie Beth Seminara
- **Activity code:** R37 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $825,474
- **Award type:** 2
- **Project period:** 2003-04-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10072296

## Citation

> US National Institutes of Health, RePORTER application 10072296, Towards Curative Therapies for Hypogonadotropic Diseases (2R37HD043341-18A1). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10072296. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*